当前位置: X-MOL 学术BBA Gen. Subj. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Receptor-based targeting of engineered nanocarrier against solid tumors: Recent progress and challenges ahead
Biochimica et Biophysica Acta (BBA) - General Subjects ( IF 3 ) Pub Date : 2020-10-29 , DOI: 10.1016/j.bbagen.2020.129777
Md. Habban Akhter , Sarwar Beg , Mohammed Tarique , Arshi Malik , Sarah Afaq , Hani Choudhry , Salman Hosawi

Background

In past few decades, the research on engineered nanocarriers (NCs) has gained significant attention in cancer therapy due to selective delivery of drug molecules on the diseased cells thereby preventing unwanted uptake into healthy cells to cause toxicity.

Scope of review

The applicability of enhanced permeability and retention (EPR) effect for the delivery of nanomedicines in cancer therapy has gained limited success due to poor accessibility of the drugs to the target cells where non-specific payload delivery to the off target region lack substantial reward over the conventional therapeutic systems.

Major conclusions

In spite of the fact, nanomedicines fabricated from the biocompatible nanocarriers have reduced targeting potential for meaningful clinical benefits. However, over expression of receptors on the tumor cells provides opportunity to design functional nanomedicine to bind substantially and deliver therapeutics to the cells or tissues of interest by alleviating the bio-toxicity and unwanted effects. This critique will give insight into the over expressed receptor in various tumor and targeting potential of functional nanomedicine as new therapeutic avenues for effective treatment.

General significance

This review shortly shed light on EPR-based drug targeting using nanomedicinal strategies, their limitation, and advances in therapeutic targeting to the tumor cells.



中文翻译:

基于受体的工程纳米载体针对实体瘤的靶向:最新进展和未来挑战

背景

在过去的几十年中,由于药物分子在患病细胞上的选择性输送,从而防止了有害细胞被健康细胞吸收而引起毒性,因此工程化纳米载体(NCs)的研究在癌症治疗中受到了广泛关注。

审查范围

由于药物对靶细胞的可及性较差,其中非特异性有效载荷向离靶区域的输送缺乏对靶细胞的实质性奖励,因此增强的通透性和保留(EPR)效应在癌症治疗中的适用性获得了有限的成功。常规治疗系统。

主要结论

尽管如此,由生物相容性纳米载体制成的纳米药物却降低了靶向潜力,可带来有意义的临床益处。然而,受体在肿瘤细胞上的过度表达提供了设计功能性纳米药物的机会,从而可以通过减轻生物毒性和有害作用而实质上结合并向目标细胞或组织递送治疗剂。这种批评将深入了解各种肿瘤中过度表达的受体,并将功能性纳米药物的靶向潜力作为有效治疗的新治疗途径。

一般意义

这篇综述很快阐明了使用纳米医学策略的基于EPR的药物靶向,其局限性以及对肿瘤细胞的治疗靶向进展。

更新日期:2020-11-17
down
wechat
bug